[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tips\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tips":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,75,113,141,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100617763","phase-3-deb-tace-vs-ctace-in-hcc-after-tips-100617763",false,"NCT07322848","DEB-TACE vs cTACE in HCC After TIPS","Drug Eluting Beads Transarterial Chemoembolization Versus Conventional Transarterial Chemoembolization for Beyond-Milan-Criteria Hepatocellular Carcinoma After Transjugular Intrahepatic Portosystemic Shunt: A Phase 3, Open Label, Multicenter, Randomized Controlled Trial","UPGRADE","Inclusion Criteria:\n\n1. histologically or clinically confirmed primary hepatocellular carcinoma, beyond Milan criteria (single lesion \\>5 cm OR ≥3 lesions with at least one ≥3 cm). At least one intrahepatic measurable lesion with tumor burden ≤50%, no distant metastasis. No prior antitumor therapy within 12 months before enrollment.\n2. underwent TIPS procedure for secondary prevention of variceal bleeding or refractory ascites. Confirmed patent TIPS at 1-month follow-up with portosystemic blood flow visible throughout the shunt and Doppler velocity \\> 60 cm\u002Fs.\n3. child-Pugh class A or B.\n4. estimated survival ≥3 months.\n5. adequate organ function:Neutrophils ≥1.5 × 10⁹\u002FL; Platelets ≥50 × 10⁹\u002FL; Hemoglobin ≥90 g\u002FL; Serum albumin ≥30 g\u002FL; Bilirubin ≤50 μmol\u002FL; AST\u002FALT ≤5 × upper limit of normal (ULN), ALP ≤4 × ULN; INR ≤2.3; Creatinine ≤1.5 × ULN.\n\nExclusion Criteria:\n\n1. diffuse hepatic infiltration, unassessable lesions on imaging, or tumor burden \\>50%.\n2. simultaneous portal vein branch tumor thrombus or main portal vein tumor thrombus.\n3. underwent liver transplantation or antitumor therapy after TIPS placement.\n4. contraindications to TACE (e.g., portosystemic shunt, hepatofugal blood flow, significant atherosclerosis).\n5. presence of brain metastases.\n6. Allergy to contrast agents.\n7. pregnancy, breastfeeding, or planning pregnancy within 2 years.\n8. co-infection with HIV or syphilis.\n9. concurrent other malignancy or history of other malignancy within the past 5 years.\n10. severe cardiac, renal, or other organ dysfunction.\n11. active clinically severe infection \\> Grade 2 (per NCI-CTC v5.0).\n12. psychiatric\u002Fpsychological conditions that may impair informed consent.\n13. participation in other drug clinical trials within 12 months prior to enrollment.","ALL","18 Years","75 Years",{"count":21,"type":22},206,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional Transarterial Chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC) that is beyond the Milan criteria and who have previously undergone a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure. The TIPS procedure is commonly performed to manage complications of portal hypertension, such as variceal bleeding or refractory ascites, in patients with cirrhosis. However, after TIPS, treatment options for HCC-particularly in cases exceeding the Milan criteria-remain limited and not well-defined in current guidelines.\n\nWhile TACE is a standard locoregional therapy for intermediate-stage HCC, its application in patients with a prior TIPS is controversial due to altered hepatic hemodynamics, which may increase the risk of liver toxicity and compromise treatment safety and efficacy. Preliminary retrospective data suggest that DEB-TACE, which uses calibrated drug-eluting microspheres, may offer a safer and more effective alternative to cTACE in this specific patient population by providing more controlled drug delivery and potentially reducing systemic and hepatic toxicity.\n\nThe primary objective of this study is to determine whether DEB-TACE improves Overall Survival (OS) compared to cTACE in patients with beyond-Milan HCC after TIPS. Secondary objectives include comparing the safety profile, Progression-Free Survival (PFS), Objective Response Rate (ORR), Disease Control Rate (DCR), and Quality of Life (QoL) between the two treatment arms.\n\nThe study aims to enroll 206 participants who will be randomly assigned in a 1:1 ratio to receive either DEB-TACE or cTACE. The trial will include a 24-month recruitment period and a 24-month treatment and follow-up phase, with a total study duration of 48 months. By directly comparing these two TACE approaches in a prospectively defined and randomized setting, this study seeks to provide high-level evidence to guide the optimal locoregional treatment strategy for HCC patients with a history of TIPS placement.",[28,29,30,31,32],"Hepatocellular Carcinoma (HCC)","TACE","TIPS","DEB-TACE","cTACE","RECRUITING","2026-04-27",{"date":36,"type":37},"2026-05-01","ACTUAL",{"date":39,"type":37},"2025-12-01",{"date":41,"type":22},"2029-12-31",{"name":43,"class":44},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100627882","phase-1-evaluation-of-the-outcome-of-fecal-microbiota-transplantation-100627882","NCT07454408","Evaluation of the Outcome of Fecal Microbiota Transplantation","A Clinical Randomized Controlled Study on the Prevention and Treatment of Drug-refractory Hepatic Encephalopathy After TIPS With Fecal Microbiota Transplantation","Inclusion Criteria:\n\n* Aged between 18 and 75 years old\n* Patients who have experienced esophageal-gastric variceal bleeding or recurrent refractory ascites and meet the inclusion criteria, and for whom conservative treatment has failed, are planned to undergo elective TIPS surgery\n* Patients with recurrent hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS), despite treatment with lactulose and rifaximin (at least 2 episodes of West Haven grade ≥2 HE within 6 months under lactulose and rifaximin intervention)\n* Provided written informed consent from the patient\n\nExclusion Criteria:\n\n* Malignant tumors of the liver, gastrointestinal tract or other systems\n* Uncontrolled severe active infection (\\>grade 2) or sepsis\n* Spontaneous bacterial peritonitis\n* Complicated with severe cardiac, renal or pulmonary insufficiency\n* Other neuropsychiatric diseases, including dementia\n* Budd-Chiari syndrome\n* Alcohol dependence or use of psychotropic drugs (benzodiazepines, opioids, etc.)\n* History of gastrointestinal surgery (e.g., colectomy) within 3 months before enrollment\n* Pregnant or lactating subjects\n* Poor compliance judged by the investigator\n* Model for End-Stage Liver Disease (MELD) score \\>17\n* Tumor, immunodeficiency, or receiving immunosuppressive therapy within 3 months before enrollment\n* Patients who have used other prebiotics, probiotics or fecal microbiota transplantation (FMT) before enrollment",true,{"count":55,"type":22},40,[57,58],"PHASE1","PHASE2","This study is a randomized, placebo-controlled, exploratory phase II clinical trial led by Professor Han Gyeong-ho from the Digestive Disease Hospital of Xi'an International Medical Center. The study enrolled 40 patients who had experienced recurrence of hepatic encephalopathy despite treatment with rifaximin and lactulose. These patients were randomly divided 1:1 into the experimental group and the control group. After obtaining informed consent from the patients, fecal microbiota transplantation or placebo control was performed. The fecal microbiota was sourced from the feces of healthy individuals who had a rich composition of the Muribaculaceae, Ruminococcaceae, and Bifidobacteriaceae families and did not contain pathogenic bacteria. The safety and efficacy of the treatment were followed up, and blood and fecal samples were collected for sequencing analysis. The aim was to provide new solutions for patients with hepatic encephalopathy who did not respond to the treatment with rifaximin and lactulose after TIPS surgery; and to explore the impact of microbiota changes and translocation on the recurrence of hepatic encephalopathy after TIPS surgery.",[61,62,30],"Hepatic Encephalopathy","Fecal Microbiota Transplantation",[61,62,30,64],"FMT","NOT_YET_RECRUITING","2026-03-05",{"date":68,"type":37},"2026-03-06",{"date":70,"type":22},"2026-03-07",{"date":72,"type":22},"2028-06-30",{"name":74,"class":44},"Air Force Military Medical University, China",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":45},"100597412","phase-4-optimizing-portal-hypertension-with-tips-and-interval-metabolic-surgery-for-advanced-liver-disease-100597412","NCT07058155","Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","OPTIMAL Trial: Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","OPTIMAL","Inclusion Criteria\n\n1. Candidate for general anesthesia.\n2. Age 18-70 years at consent.\n3. BMI 35-70 kg\u002Fm² at first study visit.\n4. Eligible for sleeve gastrectomy per ASMBS\u002FIFSO 2022 guidelines.\n5. Insurance coverage for metabolic surgery.\n6. Current or prior anti-obesity medication use permitted.\n7. Liver cirrhosis confirmed by biopsy or non-invasive assessment.\n8. Clinically significant portal hypertension (HVPG ≥ 10 mm Hg, or esophagogastric varices \u002F portal-hypertensive gastropathy, or imaging evidence of collaterals\u002Fdilated portal vein).\n9. Able and willing to provide informed consent and comply with study procedures.\n10. Women of child-bearing potential: negative urine pregnancy test at screening and randomization and agreement to reliable contraception for 2 years.\n\nExclusion Criteria\n\n1. Prior bariatric\u002Fmetabolic surgery (except removed devices ≥ 3 months earlier).\n2. Prior complex foregut surgery.\n3. History of solid-organ transplant.\n4. Severe pulmonary disease (FEV1 \\\u003C 50 % predicted).\n5. Significant cardiac or atherosclerotic disease with planned re-vascularization within 12 months.\n6. ASA class IV or V uncompensated cardiopulmonary disease.\n7. Left-ventricular ejection fraction \\\u003C 25 % or MI\u002Funstable angina\u002Fstroke\u002Fheart surgery\u002Fcoronary stent within 6 months.\n8. Hiatal hernia \\> 7 cm or LA grade C\u002FD erosive esophagitis.\n9. Active Crohn's disease.\n10. Severe psychiatric illness, dementia, active psychosis, history of suicide attempt, or alcohol\u002Fsubstance abuse within 12 months.\n11. Pregnant, breastfeeding, planning pregnancy, or not using adequate contraception.\n12. Malignancy within the prior 12 months (except non-melanoma skin cancer).\n13. Life expectancy \\\u003C 2 years in investigator's judgment.\n14. Investigational therapy within 3 months.\n15. Acute pancreatitis ≤ 90 days.\n16. Portal vein thrombosis at screening.\n17. Decompensated cirrhosis (moderate\u002Flarge ascites, hepatic encephalopathy, or listed for liver transplant); small ascites or prior variceal bleed allowed.\n18. Total bilirubin \\> 3 mg\u002FdL, INR \\> 1.7, or platelets \\\u003C 50 000\u002FµL (within 1 month).\n19. Significant alcohol intake (\\> 14 units\u002Fweek women, \\> 21 units\u002Fweek men) within the prior 12 months.\n20. eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m² or on dialysis (within 1 month).\n21. AIDS.\n22. Unable to understand study or give consent.\n23. Plans to move more than 3 hours from Cleveland within 6 months.\n24. Previous randomization in this trial.\n25. Any condition that, in the investigator's opinion, places the subject at undue risk.","70 Years",{"count":85,"type":22},70,[87],"PHASE4","Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present.\n\nThis study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes.\n\nThe study will compare two groups:\n\n1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG).\n2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications).\n\nAll participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups.\n\nThe main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment.\n\nParticipants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes.\n\nThis study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.",[90,91,92,30],"Liver Cirrhoses","Portal Hypertension Related to Cirrhosis","Severe Obesity",[94,95,96,97,98,99,100,101,102,103],"Sleeve Gastrectomy","Transjugular Intrahepatic Portosystemic Shunt (TIPS)","Bariatric Surgery \u002F Metabolic Surgery","Clinically Significant Portal Hypertension (CSPH)","Health-Related Quality of Life (HRQOL)","SF-36 Questionnaire","Weight Loss","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Randomized Controlled Trial","2025-12-20",{"date":106,"type":37},"2025-12-23",{"date":108,"type":37},"2025-12-17",{"date":110,"type":22},"2034-02-01",{"name":112,"class":44},"The Cleveland Clinic",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100613987","udca-to-prevent-post-tips-hepatic-encephalopathy-100613987","NCT07273734","UDCA to Prevent Post-TIPS Hepatic Encephalopathy","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ursodeoxycholic Acid Plus Lactulose vs Lactulose Alone for the Prevention of Overt Hepatic Encephalopathy After TIPS Placement","THEUDCA","Inclusion Criteria:\n\n* Age 18-80 years.\n* Confirmed cirrhosis (biopsy, elastography, or standard radiologic\u002Fbiochemical criteria).\n* Elective TIPS for (a) refractory\u002Frecurrent ascites and\u002For (b) recurrent variceal bleeding not responsive to treatment with endoscopic band ligation and beta-blockers.\n* Preemptive TIPS for patients with variceal bleeding and Child-Pugh C (10-13 points), patients with Child-Pugh B and active bleeding during endoscopy, or patients with hepatic venous pressure gradient (HVPG) ≥ 20 mmHg.\n* Ability to start study drug within 72 hours before TIPS.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Contraindications to TIPS (e.g., severe heart failure ≥NYHA III, severe pulmonary hypertension, uncontrolled sepsis, advanced HCC at risk with TIPS, unrelieved biliary obstruction, Child-Pugh score \\>13, main-trunk PVT if not recanalizable, technical infeasibility).\n* Prior OHE grade II-IV without precipitating factor; overt neurological disease affecting cognition (e.g., Parkinson's, Alzheimer's).\n* Current or planned ursodeoxycholic acid (UDCA) therapy for an approved indication (e.g., primary biliary cholangitis), or UDCA use within the prior 3 months.\n* Current\u002Frecent rifaximin use (\\\u003C3 months) or strong UDCA contraindication\u002Fhypersensitivity.\n* Salvage TIPS.\n* Non-cirrhotic portal hypertension.\n* Pregnancy\u002Flactation.\n* Any condition that, in investigators' judgment, precludes safe participation.","80 Years",{"count":123,"type":22},270,[125],"NA","Hepatic encephalopathy (HE) commonly occurs after transjugular intrahepatic portosystemic shunt (TIPS). Ursodeoxycholic acid (UDCA) has been reported to alleviate neurodegenerative disease recently. This open-label multicenter randomized controlled trial tests whether adding UDCA (13-15 mg\u002Fkg\u002Fday) to standard lactulose prophylaxis reduces the incidence of overt HE (OHE; West Haven grade II-IV) after TIPS, compared with lactulose alone. The regimen starts within 72 hours before TIPS and continues for 3 months. The trial aims to evaluate the effect of UDCA in reducing the incidence of post-TIPS OHE.",[128,30],"Hepatic Encephalopathy (HE)",[30,130,128,131],"UDCA","Ursodeoxycholic acid","2025-11-26",{"date":134,"type":37},"2025-12-09",{"date":136,"type":22},"2026-01-01",{"date":138,"type":22},"2027-12-31",{"name":140,"class":44},"West China Hospital",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":45},"100605528","tips-for-complicated-portal-hypertension-related-to-porto-sinusoidal-vascular-disease-100605528","NCT07163689","TIPS for Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS for the Management of Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS-PSVD","Inclusion Criteria:\n\n* PSVD group :\n* Patient with PSVD according VALDIG criteria\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n* Cirrhosis group with PH : (appaired by age, sexe, type of PH complications)\n* Confirmed cirrhosis with :\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n\nExclusion Criteria:\n\n* no PSVD confirmed diagnosis\n* Budd Chiari syndrome\n* Rendu Osler disease; Heart failure\n* Fontan; Sarcoïdosis\n* Schistosomiase\n* Congenitale liver fibrosis\n* Abernathy syndrome\n* Tumor infiltration by lymphoma\n* Bone graft",{"count":150,"type":22},360,"OBSERVATIONAL","Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related.\n\nThe study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition",[30,154,155,156,157,158],"Portal Hypertension","Porto-Sinusoidal Vascular Disease","Refractory Ascite","Esophageal Varices","Gastrointestinal Hemorrhage",[30,160,161,162,163,164],"Portal hypertension","Porto-Sinusoidal Vascular disease","refractory ascite","esophageal varices","gastrointestinal hemorrhage","2025-11-18",{"date":167,"type":37},"2025-11-19",{"date":169,"type":37},"2025-05-16",{"date":171,"type":22},"2025-12",{"name":173,"class":44},"Centre Hospitalier Universitaire, Amiens",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100578722","acquisition-of-cardiac-function-parameters-in-mri-and-echocardiography-in-patients-with-ethyltoxic-liver-cirrhosis-and-transjugular-intrahepatic-portosystemic-shunt-tipss-placement-100578722","NCT06814990","Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement","Erfassung Kardialer Funktionsparameter in MRT Und Echokardiographie Bei Patienten Mit Ethyltoxischer Leberzirrhose Und Transjugulärer Intrahepatischer Portosystemischer Shunt (TIPSS)-Anlage","EVALUATION","Inclusion Criteria:\n\n* Age 18 to 99 years\n* Written informed consent of the patient\n* Decompensated liver cirrhosis, defined by clinical, imaging or laboratory criteria\n* Patient receives an elective TIPSS in the appropriate clinical context at the JUH\n\nExclusion Criteria:\n\n* Pregnancy\n* Implants not suitable for magnetic resonance imaging\n* Medical\u002Fpersonal reasons against magnetic resonance imaging (claustrophobia, patient cannot lie flat or follow breathing commands)\n* Patient in critical condition or incompliant","99 Years",{"count":184,"type":22},80,[125],"The aim of this clinical trial is to investigate the development of cardiac decompensation following transjugular intrahepatic portosystemic shunt (TIPSS) implantation in order to draw conclusions for future treatment methods or exclusion criteria prior to TIPS implantation.\n\nThe main questions to be answered are:\n\nHow often do symptoms of cardiac decompensation develop over a one year period? What laboratory, clinical or imaging morphological changes are associated with this? In addition to the standardised clinical procedure for TIPSS implantation, participants will undergo 3 cardiac magnetic resonance imaging (MRI), extended echocardiographic examinations (both just before, 3 days after and 3 months after implantation) and laboratory chemistry tests for specific endothelial and inflammatory markers (just before, on the day of implantation, 1 day after, 1, 3, 6 and 12 months after implantation).",[188,189,190,191,30],"MASLD","Liver Cirrhosis, Alcoholic","Cirrhosis of Liver","Heart Decompensation",[193,194,30],"Chirrotic cardiomyopathy","Liver chirrosis","2025-02-11",{"date":197,"type":37},"2025-02-13",{"date":199,"type":37},"2024-04-19",{"date":201,"type":22},"2027-04-19",{"name":203,"class":44},"Stephanie Gräger"]